Interventions utilizing a range of inhibitors at the in vitro level, including the PDGFR-β inhibitor AG1296, the PI3K inhibitor LY294002, the AKT inhibitor MK2206, and the FAK inhibitor Y15, demonstrated that E. multilocularis protoscoleces protein (EmP) induces angiogenesis through PDGFR/PI3K/AKT/FAK signaling pathway. Our findings provide new perspectives on how E. multilocularis infection triggers pathological angiogenesis in the host liver, and may provide a novel anti-angiogenic therapeutic strategy against E. multilocularis infection.

P1, N=36, Recruiting, University of Chicago | Active, not recruiting --> Recruiting

P3, N=930, Recruiting, Ocular Therapeutix, Inc.

P2, N=45, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Oct 2029 --> Oct 2030

P1/2, N=38, Recruiting, Indiana University | Not yet recruiting --> Recruiting | Trial completion date: Mar 2032 --> Sep 2031

P2, N=48, Not yet recruiting, Third Medical Center, Chinese PLA General Hospital; Chinese PLA General Hospital

P4, N=35, Not yet recruiting, The First Affiliated Hospital of Zhengzhou University​; The First Affiliated Hospital of Zhengzhou University?

PSA showed rilertinib's cost-effective probabilities were 51.6% at one-time GDP per capita and 90.2% at three-times GDP per capita ($40,334.05) WTP threshold. From a Chinese healthcare system perspective, second-line treatment of EGFR T790M resistance mutation advanced NSCLC with rilertinib may have cost-effectiveness compared with osimertinib.

P1, N=18, Recruiting, Washington University School of Medicine | Not yet recruiting --> Recruiting

STELLAR-303 is the first phase 3 trial to show a significant improvement in overall survival with an immunotherapy-based regimen, zanzalintinib-atezolizumab, in patients with relapsed or refractory metastatic colorectal cancer that is not MSI-H or dMMR. This combination represents a chemotherapy-free treatment option with a novel mechanism of action for heavily pretreated patients in need of improved therapies.

P3, N=901, Active, not recruiting, Exelixis | Trial completion date: Feb 2026 --> Jan 2027 | Trial primary completion date: Aug 2025 --> May 2026

This study demonstrates that ANXA3 regulates ERS to drive M1 macrophage polarization and inflammation, which subsequently promotes PASMC function and promotes PAH progression. ANXA3 may serve as a novel immunoinflammatory target and potential therapeutic candidate.